To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
Trabecular outflow facility is a measure of aqueous humor dynamics; effect of netarsudil on this parameter as well as on intraocular pressure and episcleral venous pressure was evaluated in this study. Netarsudil treatment was given in one eye and placebo given in contralateral eye for 7 consecutive days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
20
1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
Mayo Clinic
Rochester, Minnesota, United States
Duke Eye Center
Durham, North Carolina, United States
Mean Change From Baseline in the Mean Diurnal Trabecular Outflow Facility
Mean diurnal change from baseline in trabecular (tonographic) outflow facility.
Time frame: Study treatment was administered for 7 days, and outcome measures collected on Day 8
Mean Percent Change From Baseline in the Mean Diurnal Trabecular Outflow Facility.
Mean diurnal change from baseline in trabecular (tonographic) outflow facility.
Time frame: Study treatment was administered for 7 days, and outcome measures collected on Day 8
Mean Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)
Mean diurnal change from baseline in mean diurnal IOP measured using a Pneumatonometer and mean diurnal EVP using a custom-modified slit-lamp mounted venomanometer. (EVP conducted at a single site in only 9 participants)
Time frame: Study treatment was administered for 7 days, and outcome measures collected on Day 8
Mean Percent Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)
Mean diurnal change from baseline in mean diurnal IOP measured using a Pneumatonometer and mean diurnal EVP using a custom-modified slit-lamp mounted venomanometer. (EVP conducted at a single site in only 9 participants)
Time frame: Study treatment was administered for 7 days, and outcome measures collected on Day 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.